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Cholestasis and thrombocytopenia are complications that aﬀect infants born small for gestational age 
(SGA).  In SGA infants,  other vital organs develop at the expense of the liver,  and the thrombopoietin 
produced by the liver is low,  often resulting in cholestasis.  We hypothesized that thrombocytopenia at 
birth can be used to predict cholestasis in very-low-birth-weight infants (VLBWIs) with SGA.  This 
retrospective cohort study enrolled VLBWIs with SGA admitted to a tertiary neonatal intensive care 
unit.  A platelet cutoﬀ value predictive of cholestasis was determined using receiver operating charac-
teristic analysis.  Multivariate logistic regression analysis was performed to evaluate the platelet cutoﬀ 
value,  and adjusted odds ratios (ORs) and 95ｵ conﬁdence intervals (CIs) were calculated.  Regarding 
the onset of cholestasis,  survival analysis was performed by calculating the adjusted hazard ratios 
(HRs) and 95ｵ CIs.  A total of 87 infants were evaluated,  and the platelet cutoﬀ value was determined 
as 88×103 cells/µl.  The adjusted OR for this platelet cutoﬀ value was 10.52 (95ｵ CI 2.26-55.93,  p＝
0.003),  and the adjusted HR was 7.76 (95ｵ CI 2.51-23.50,  p＝0.0006).  Thrombocytopenia is a useful 
predictor for cholestasis in VLBWIs with SGA.
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holestasis is one of many complications observed 
in infants born small for gestational age (SGA) 
and is associated with an increased risk of mortality 
[1].  The etiology of neonatal cholestasis is multifac-
torial,  and includes asphyxia,  total parenteral nutri-
tion,  sepsis,  necrotizing enterocolitis,  gastrointesti-
nal surgery,  and fasting [2-9].
　 Thrombocytopenia is another complication in SGA 
infants [10].  Platelet counts in SGA infants are 
typically 100-150×103 cells/µl at birth,  followed by 
a nadir at day 4-5,  which resolves by day 7-10 
(＞150×103 cells/µl) [11].  Intrauterine hypoxia is 
thought to account for the impaired thrombopoiesis in 
SGA infants [12].  SGA infants with intrauterine 
hypoxia-induced thrombocytopenia have low throm-
bopoietin (TPO) blood levels [13].  The production of 
TPO,  which promotes thrombopoiesis by increasing 
platelet counts,  is normally triggered in the liver by 
thrombocytopenia [14].  However,  TPO is not typi-
cally activated in SGA infants because of liver dam-
age.  However,  few clinical reports have shown that 
thrombocytopenia is associated with cholestasis.  In 
this study,  we tested the hypothesis that thrombocy-
topenia at birth predicts cholestasis in very low birth 
weight infants (VLBWIs) who are born SGA.
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Materials and Methods
　 A retrospective cohort study of patients with 
thrombocytopenia and cholestasis was conducted in 
singleton VLBWIs born SGA who were admitted into 
the tertiary neonatal intensive care unit at Okayama 
Medical Center from January 1,  2003 to December 
31,  2010.  SGA was deﬁned as having a weight below 
the 10th percentile for normal birth weight according 
to standard values published by the Japan Pediatric 
Society [15].  Exclusion criteria included maternal 
idiopathic thrombocytopenic purpura,  multiple anoma-
lies,  chromosomal abnormalities,  congenital infec-
tions,  and neonatal autoimmune thrombocytopenia [2,  
12].
　 Perinatal and neonatal data collected at and after 
birth included birth characteristics (sex,  gestational 
age (GA),  birth weight (BW),  height,  head circum-
ference,  and Apgar scores),  cholestasis-related fac-
tors (presence or absence,  date of onset,  date of 
cure,  disease duration,  and direct bilirubin (DBIL) 
concentration),  discharge information (transfer,  dis-
charge,  or death),  total parenteral nutrition,  sepsis,  
necrotizing enterocolitis (NEC),  gastrointestinal sur-
gery,  fasting,  maternal diseases during pregnancy 
(pregnancy-induced hypertension and diabetes melli-
tus),  complete blood count,  and blood gas values (pH,  
pCO2,  and base excess).  Sepsis was diagnosed by 
blood culture.  We deﬁned fasting as the discontinua-
tion of enteral feeding.  DBIL concentration was 
measured once a week,  and cholestasis was deﬁned as 
DBIL concentration ＞2.0mg/dl [2].  Date of onset 
was deﬁned as the day DBIL concentration exceeded 
2.0mg/dl,  and date of cure was deﬁned as the day 
DBIL concentration was ｦ2.0mg/dl after onset.
　 Continuous data are expressed as means ± stan-
dard deviations (SDs) and compared by Studentʼs 
t-test.  Binary or categorical data are expressed as 
frequencies and percentages.  Binary data were com-
pared by chi-square test and Fisherʼs exact test.  In 
addition,  risk ratios (RRs),  mean diﬀerence (MD),  
95ｵ conﬁdent intervals (CIs),  and p-values were cal-
culated.  Thrombocytopenia is clinically deﬁned as 
platelet count ＜150×103 cells/µl [11].  In this study,  
receiver operating characteristic (ROC) analysis was 
used to determine a cutoﬀ value predictive of 
cholestasis.  Sensitivity,  speciﬁcity,  positive likeli-
hood ratio,  positive predictive value (PPV),  negative 
predictive value (NPV) and area under the curve 
(AUC) were calculated.
　 Univariate and multivariate logistic regression 
analysis were performed to evaluate the platelet cutoﬀ 
value,  and the odds ratios (ORs) and corresponding 
95ｵ CIs were calculated.  Kaplan-Meier survival 
curves were generated to estimate the risk of 
cholestasis.  Also,  hazard ratios (HR),  corresponding 
95ｵ CIs,  and p-values were calculated using univari-
ate and multivariate Cox regression analysis.  The 
following potential confounding factors for the platelet 
cutoﬀ value at birth were used in multivariate logistic 
regression analysis: 5-min Apgar score,  severe SGA,  
hemoglobin (Hb),  and platelet count.  The 5-min Apgar 
score was used to assess asphyxia [4,  9].  A previous 
report showed that infants with severe SGA were at 
an increased risk of cholestasis [1].  Severe SGA was 
deﬁned in this study as follows: GA ｧ35wk and 
＜40wk and BW ＜1,500g; GA ｧ33wk and ＜35wk,  
and BW ＜1,250g; GA ｧ31wk and ＜33wk,  and BW 
＜1,000g; GA ｧ29wk and ＜31wk,  and BW ＜750g;  
or GA ｧ27wk and ＜29wk and BW ＜500g.  Hb lev-
els were selected as a potential confounding factor,  
because Hb levels are associated with liver function in 
SGA infants [16,  17].  Hb/5 was used a value divided 
Hb by 5 for the analysis.  All statistical analyses were 
performed using JMP 7.0.1 (SAS Institute,  Inc.,  
Cary,  NC,  USA).  This study was approved by the 
Okayama Medical Center ethics committee.
Results
　 A total of 87 infants were evaluated in this study.  
Forty infants exhibited thrombocytopenia (platelet 
count ＜150×103 cells/µl; mean GA,  31.7±3.3 week;  
mean BW,  966±334g),  and 47 infants did not exhibit 
thrombocytopenia (platelet count ｧ150×103 cells/µl;  
mean GA,  31.6±2.9 week; mean BW,  1,069±267g;  
Table 1).  The thrombocytopenia group had a lower 
Apgar score (1 min),  lower birth weight,  higher 
WBC,  and greater numbers of TPN and fasting cases 
than the non-thrombocytopenia group.  Cholestasis was 
observed in 9 infants (23ｵ) with thrombocytopenia 
and 4 infants (8.5ｵ) without thrombocytopenia,  with 
RR 2.64,  95ｵ CI 0.88-7.94,  p＝0.079,  sensitivity 
0.69,  speciﬁcity 0.58 (1-speciﬁcity＝0.42),  positive 
likelihood ratio 1.65,  PPV 0.23 and NPV 0.91.
　 The platelet concentration of ＜88×103 cells/µl 
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was chosen as the cutoﬀ value for predicting cholesta-
sis (sensitivity 0.46,  speciﬁcity 0.91 (1-speciﬁcity＝
0.09),  positive likelihood ratio 4.88,  PPV 0.46,  
NPV 0.91 and AUC 0.67).  This cutoﬀ value identi-
ﬁed 13 infants with thrombocytopenia (mean GA,  
32.6±4.3wk; mean BW,  1,032±443g) and 74 infants 
without thrombocytopenia (mean GA,  31.5±2.8wk;  
mean BW,  1,020±274g) (Table 2).  Six infants (46ｵ) 
exhibited both thrombocytopenia and cholestasis,  and 
7 infants (9.5ｵ) exhibited cholestasis but not throm-
bocytopenia (RR 4.88,  95ｵ CI 1.95-12.21,  p＝0.0006).
　 The results for cholestasis-predictive factors were 
as follows: platelet counts ＜150×103 cells/µl,  OR
＝2.64,  95ｵ CI＝0.88-7.94,  p＝0.079 and adjusted 
OR＝4.33,  95ｵ CI＝1.13-20.26,  p＝0.032,  for 
platelet counts ＜88×103 cells/µl,  OR＝4.88,  95ｵ 
CI＝1.95-12.21,  p＝0.0006 and adjusted OR＝10.52,  
95ｵ CI＝2.26-55.93,  p＝0.003 (Table 3).
　 Kaplan-Meier analysis revealed an increased risk 
for cholestasis among infants with thrombocytopenia 
(platelet count ＜150×103 cells/µl or 88×103 cells/
µl) (Fig.  1).  Cox regression analysis of platelet cutoﬀ 
values yielded an HR of 2.48 (95ｵ CI,  0.88-7.97,  
p＝0.086) and adjusted HR of 3.35 (95ｵ CI,  1.12-
11.30,  p＝0.031) for 150×103 cells/µl,  and an HR of 
7.09 (95ｵ CI,  2.46-20.04,  p＝0.0006) and adjusted 
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Table 1　 Clinical characteristics and laboratory data (platelet cutoﬀ value: 150×103 cells/µl)
Platelet count
RR or MD (95% CI) p-value＜150×103 cells/µl
(n＝40)
ｧ150×103 cells/µl
(n＝47)
At birth Primiparity 20 (50%) 25 (53%) 0.94 (0.62-1.42) 0.767
Maternal PIH 15 (38%) 12 (26%) 1.47 (0.78-2.76) 0.229
Maternal DM 0 (0%) 0 (0%) - -
Male gender 20 (50%) 18 (38%) 1.31 (0.81-2.10) 0.273
Apgar score (1 min) 5.8 (2.5) 7.2 (1.4) －1.40 (－2.24-－0.55) 0.001
Apgar score (5 min) 7.5 (2.3) 8.3 (1.3) －0.75 (－1.53-0.02) 0.057
Gestational age (wk) 31.7 (3.3) 31.6 (2.9) 0.12 (－1.21-1.45) 0.853
Birth weight (g) 966 (334) 1,069 (267) －104 (－231-25) 0.112
Birth weight (SD) －3.2 (1.0) －2.6 (0.9) －0.60 (－1.00-－0.19) 0.004
Severe SGA 20 (50%) 15 (32%) 1.57 (0.93-2.64) 0.086
Birth height (cm)＊ 34.2 (4.7) 35.3 (3.4) －1.09 (－2.84-0.65) 0.216
Birth height (SD)＊ －2.7 (1.3) －2.3 (0.9) －0.39 (－0.86-0.08) 0.104
Birth head circumference (cm)＊ 26.2 (3.2) 26.1 (3.3) 0.10 (－1.28-1.49) 0.882
Birth head circumference (SD)＊ －1.4 (1.6) －1.4 (1.0) 0.10 (－0.48-0.67) 0.741
pH 7.246 (0.120) 7.287 (0.113) －0.041 (－0.091-0.009) 0.103
pCO2 (mm Hg) 51.9 (14.0) 51.0 (9.9) 0.97 (－4.16-6.09) 0.709
Base excess (mmol/l) －6.2 (5.5) －4.3 (3.8) －1.95 (－3.94-0.05) 0.056
WBC (×103 cells/µl) 18.5 (13.6) 14.5 (14.3) 4.01 (－1.97-10.00) 0.186
Hb (g/dl) 17.0 (3.0) 16.6 (3.5) 0.47 (－0.92-1.86) 0.503
Platelet (×103 cells/µl) 106 (33) 226 (74) －120 (－145-－95) ＜0.0001
After birth Cholestasis 9 (23%) 4 (8.5%) 2.64 (0.88-7.94) 0.079
Onset of cholestasis (day) 15.4 (17) 17.8 (26.2) －2.31 (－28.30-23.69) 0.849
Cure of cholestasis (day) 36.9 (10.3) 45.5 (15.5) －8.61 (－49.67-32.45) 0.653
TPN 24 (60%) 17 (36%) 1.66 (1.05-2.62) 0.027
Sepsis 3 (7.5%) 3 (6.4%) 1.18 (0.25-5.50) 1.000
NEC 0 (0%) 1 (2.1%) 0 (-) 1.000
Gastrointestinal surgery 2 (5.0%) 2 (4.3%) 1.18 (0.17-7.97) 1.000
Fasting 7 (17.5%) 3 (6.4%) 2.74 (0.76-9.91) 0.176
Data are expressed as means (± standard deviations) or numbers of cases (percent).
RR,  risk ratio; MD,  mean diﬀerence; CI,  conﬁdence interval; PIH,  pregnancy-induced hypertension; DM,  diabetes mellitus; WBC,  white 
blood cell; Hb,  hemoglobin; TPN,  total parenteral nutrition; NEC,  necrotizing enterocolitis.
＊Indicates cases lacking birth height and head circumference data.
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Table 3　 Multivariate logistic regression analysis of platelet concentration as a predictor of cholestasis
Adjusted OR 95% CI p value
Apgar score (5 min)  1.40 0.95-2.55 0.102
Severe SGA  1.85 0.50-7.17 0.357
Hb/5  0.30 0.10-0.82 0.018
Platelet ＜150×103/µl  4.33 1.13-20.26 0.032
Adjusted OR 95% CI p value
Apgar score (5 min)  1.53 0.99-2.97 0.060
Severe SGA  1.74 0.44-7.11 0.425
Hb/5  0.39 0.13-1.08 0.069
Platelet ＜88×103/µl 10.52 2.26-55.93 0.003
OR,  odds ratio; CI,  conﬁdence interval.
Table 2　 Clinical characteristics and laboratory data (platelet cutoﬀ value: 88×103 cells/µl)
Platelet count
RR or MD (95% CI) p-value＜88×103 cells/µl
(n＝13)
ｧ88×103 cells/µl
(n＝74)
At birth Primiparity 9 (69%) 36 (49%) 1.42 (0.92-2.19) 0.233
Maternal PIH 6 (46%) 21 (28%) 1.63 (0.82-3.24) 0.201
Maternal DM 0 (0%) 0 (0%) - -
Male 3 (23%) 35 (47%) 0.49 (0.18-1.35) 0.135
Apgar score (1 min) 5.3 (2.8) 6.7 (1.9) －1.44 (－2.65-－0.22) 0.021
Apgar score (5 min) 7.2 (2.4) 8.1 (1.7) －0.91 (－2.00-0.18) 0.099
Gestational age (wk) 32.6 (4.3) 31.5 (2.8) 1.13 (－0.72-2.97) 0.228
Birth weight (g) 1,032 (443) 1,020 (274) 12 (－169-194) 0.894
Birth weight (SD) －3.4 (1.0) －2.8 (1.0) －0.64 (－1.22-－0.06) 0.031
Severe SGA 8 (62%) 27 (36%) 1.69 (0.998-2.85) 0.089
Birth height (cm)＊ 34.3 (6.8) 34.9 (3.4) －0.59 (－3.04-1.86) 0.633
Birth height (SD)＊ －3.0 (1.1) －2.4 (1.1) －0.54 (－1.19-－0.12) 0.107
Birth head circumference (cm)＊ 26.9 (4.6) 26.0 (2.9) 0.92 (－1.00-2.84) 0.344
Birth head circumference (SD)＊ －1.2 (2.4) －1.4 (1.1) 0.20 (－0.60-0.99) 0.620
pH 7.250 (0.079) 7.271 (0.123) －0.021 (－0.092-0.049) 0.551
pCO2 (mm Hg) 50.9 (12.6) 51.5 (11.9) －0.53 (－7.70-6.63) 0.882
Base excess (mmol/l) －6.4 (2.9) －4.9 (5.0) －1.45 (－4.28-1.38) 0.312
WBC (×103 cells/µl) 25.4 (16.6) 14.8 (13.1) 10.60 (2.46-18.74) 0.011
Hb (g/dl) 15.9 (3.8) 16.9 (3.1) －1.03 (－2.97-0.90) 0.292
Platelet (×103 cells/µl) 65 (15) 190 (77) －124 (－167-－81) ＜0.0001
After birth Cholestasis 6 (46%) 7 (9.5%) 4.88 (1.95-12.21) 0.0006
Onset of cholestasis (day) 6.5 (4.1) 24.4 (22.9) －17.93 (－38.90-3.04) 0.087
Cure of cholestasis (day) 32.0 (30.0) 46.0 (30.9) －14.00 (－51.24-23.24) 0.426
TPN 6 (46%) 35 (47%) 0.98 (0.52-1.84) 0.939
Sepsis 1 (7.7%) 5 (6.8%) 1.14 (0.14-8.97) 1.000
NEC 0 (0%) 1 (1.4%) 0 (-) 1.000
Gastrointestinal surgery 1 (7.7%) 3 (4.1%) 1.90 (0.21-16.87) 0.483
Fasting 5 (38%) 5 (6.8%) 5.69 (1.91-16.94) 0.0009
Data are expressed as means (± standard deviations) or numbers of cases (percents).
RR,  risk ratio; MD,  mean diﬀerence; CI,  conﬁdence interval; PIH,  pregnancy-induced hypertension; DM,  diabetes mellitus; WBC,  white 
blood cell; Hb,  hemoglobin; TPN,  total parenteral nutrition; NEC,  necrotizing enterocolitis.
＊Indicates cases lacking birth height and head circumference data.
HR of 7.76 (95ｵ CI,  2.51-23.50,  p＝0.0006) for 88
×103 cells/µl (Table 4).  Increased DBIL concentra-
tions were associated with both platelet cutoﬀ values.  
DBIL concentrations were very high in some infants 
with thrombocytopenia (Fig.  2).  Maximum DBIL level 
of infants with platelet count ｧ88 and ＜150×103 
cells/µl became almost 1mg/dl.
Discussion
　 In this study,  we tested whether thrombocytopenia 
(＜150×103 cells/µl) was a useful predictive factor 
for cholestasis.  In univariate analysis,  the incidences 
of cholestasis in the thrombocytopenia group were 
higher in the setting of both cutoﬀ values; 150 and 88
×103 cells/µl.  In multivariate analysis,  adjusted OR 
and adjusted HR were 4.33 and 3.35,  respectively,  
which were high.  In addition,  when using the new 
cutoﬀ value of 88×103 cells/µl,  the adjusted OR and 
adjusted HR rose to 10.52 and 7.76,  respectively.  
Thus,  thrombocytopenia would be useful for predict-
ing cholestasis.  Though NPVs for both cut-oﬀ values 
were high,  over 0.9,  the PPV for 88×103 cells/µl 
was 0.46,  which was twice as high as PPV for 150×
103 cells/µl.  But,  because the value of PPV was not 
high relatively,  we might need to investigate the new 
cutoﬀ value more precisely in a future study.  The 
high NPV showed that patients without thrombocy-
topenia were not likely to have cholestasis.  This 
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Fig. 1　 Kaplan-Meier survival analysis for cholestasis or death.  
Solid line represents infants with thrombocytopenia,  and the 
dashed line represents those without thrombocytopenia.  Platelet 
cutoﬀ values are 150×103 cells/µl (left) and 88×103 cells/µl 
(right).  Infants with thrombocytopenia were at higher risk for 
cholestasis or death.
Table 4　 Multivariate Cox regression analysis of platelet concentration as a predictor of cholestasis
Adjusted HR 95% CI p value
Apgar score (5 min) 1.12 0.88-1.52 0.386
Severe SGA 1.36 0.46-3.95 0.565
Hb/5 0.33 0.16-0.74 0.008
Platelet ＜150×103/µl 3.35 1.12-11.30 0.031
Adjusted HR 95% CI p value
Apgar score (5 min) 1.16 0.91-1.58 0.250
Severe SGA 1.25 0.41-3.79 0.693
Hb/5 0.44 0.21-0.93 0.032
Platelet ＜88×103/µl 7.76 2.51-23.50 0.0006
HR,  hazard ratio; CI,  conﬁdence interval.
Fig. 2　 Platelet cutoﬀ values are 150×103 cells/µl (upper) and 
88×103 cells/µl (lower).  Filled markers represent infants with 
thrombocytopenia,  and open markers represent those without 
thrombocytopenia.  DBIL concentrations were very high in some 
infants with thrombocytopenia.  Maximum DBIL level of infants with 
platelet count ｧ88 and ＜150×103 cells/µl became almost 1mg/
dl.
ﬁnding might also be useful in the clinical setting.  In 
this study,  we analyzed the platelet count only at 
birth,  because we wanted to check whether thrombo-
cytopenia at birth could predict cholestasis.
　 Onset of cholestasis was about 2-3 weeks after 
birth.  The onset of the thrombocytopenia cases 
(platelet ＜88×103 cells/µl) was very early (6.5±
4.1day).  The cholestasis was resolved at 32.0±30.0 
and 46.0±30.9 days in the thrombocytopenia and non-
thrombocytopenia groups,  respectively.  But the DBIL 
of the thrombocytopenia group remained high,  even at 
day 100 (Fig.  2).  The characteristic of thrombocy-
topenia group shows a quick and sustained elevation of 
DBIL to rather high levels.
　 Asphyxia was related with cholestasis in a previous 
report [9].  In our study,  the Apgar score (5 min) was 
low in the thrombocytopenia group.  However,  it did 
not have a statistically signiﬁcant OR or HR in multi-
variate analysis.  Therefore,  the association is unclear.
　 There was no diﬀerence in Hb between the throm-
bocytopenia and non-thrombocytopenia groups.  But the 
aOR and aHR of Hb/5 were less than 1.  This means 
that low Hb leads to cholestasis.  Erythropoietin,  
which activates erythrocyte production,  is produced 
in the liver [18].  And erythropoiesis occurs in the 
liver at the second trimester [19].  There might be 
relationship between Hb and cholestasis.
　 As potential causes of cholestasis,  the TPN,  sep-
sis,  NEC,  gastrointestinal surgery and fasting were 
checked.  Only fasting had higher incidence in the 
thrombocytopenia group.  These 5 factors were not 
added to multivariate analysis from the point of the 
time course,  because this studyʼs aim was to determine 
whether thrombocytopenia at birth predicted cholesta-
sis.
　 The incidence of severe SGA was higher in the 
thrombocytopenia group.  Severe SGA was expected 
to have high OR and HR,  because SGA was one of the 
causes of cholestasis.  However,  the aOR and aHR of 
severe SGA were 1.74 and 1.25 respectively,  which 
were lower than those of thrombocytopenia.  Then,  the 
impact of SGA for the thrombocytopenia was still 
unclear in the study.
　 From the pathophysiological view,  various factors 
(maternal,  placental or fetal factors) appear to cause 
SGA,  which leads to thrombocytopenia and cholesta-
sis.  In the SGA infant,  the development of the liver 
and intestine is sacriﬁced through diving reﬂex.  The 
liver has various functions.  One of them is TPO 
production.  Decreased TPO production would cause 
thrombocytopenia.  On the other hand,  if bile acid 
secretion of hepatocytes decreases temporarily,  
cholestasis would occur.  Thus,  both thrombocytope-
nia and cholestasis would be derived from liver dam-
age.  This study also showed that every SGA infant did 
not have thrombocytopenia or cholestasis; in other 
words,  SGA is a heterogeneous condition.  The pos-
sibility of predicting cholestasis by thrombocytopenia 
might reveal the presence of one subgroup of SGA,  
which easily had liver damage.  In this study,  we 
excluded chromosomal anomalies.  We could not ana-
lyze the cause of SGA because of the small number of 
cases.  In the future,  the relationship among the causes 
of SGA,  thrombocytopenia and cholestasis should be 
clariﬁed with a larger dataset.
　 One limitation of this study is that it is based on 
retrospective data collected from a single tertiary 
neonatal intensive care unit.  Prospective multicenter 
studies are needed to conﬁrm our results.  In addition,  
we could not check acquired cytomegalovirus infection 
in all patients with cholestasis.
　 Our study shows that thrombocytopenia can be used 
to predict cholestasis in VLBWIs who are born SGA.  
We determined that the platelet cutoﬀ value of 88×
103 cells/µl is useful.
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